A prospective clinical trial of implantable central venous access in children with haemophilia

摘要: To assess the risks associated with use of central venous ports in children haemophilia, 15 HIV-negative patients were prospectively evaluated. Port insertion was required for immune tolerance two inhibitor and continuous prophylaxis 13 severe factor VIII deficiency, whom surgery covered recombinant (rFVIII), then given daily at home until day 6. One patient (titre 7 BU/ml) received high-dose rFVIII by infusion 3, followed an treatment scheme; other 12 BU/ml) activated VII 7. After training on port, all continued their programme home. All remained place a median period 413 d (range 125–509). The number entries into port 184 53–567). Port-site haematoma infection occurred one 7 when became detectable 12 BU/ml). An infectious complication another after 310 d. rate 0.42 per 1000 patient-days (0.33 port). This protocol placement short hospitalization appears feasible safe.